Dactinomycin
View Brand InformationWhat is Dactinomycin?
Approved To Treat
Related Clinical Trials
Summary: This is a phase I-II study to determine safety and efficacy of combining liposomal irinotecan with vincristine alternating with VAC in intermediate-risk patients, liposomal irinotecan with temozolomide and vincristine alternating with VAC in high-risk patients and the chemotherapy combinations when given with concomitant radiation therapy in intermediate and high risk patients. Primary Objective *...
Summary: Rhabdomyosarcoma is a type of cancer that occurs in the soft tissues in the body. This phase III trial aims to maintain excellent outcomes in patients with very low risk rhabdomyosarcoma (VLR-RMS) while decreasing the burden of therapy using treatment with 24 weeks of vincristine and dactinomycin (VA) and examines the use of centralized molecular risk stratification in the treatment of rhabdomyosa...
Summary: This clinical trial will evaluate 4 different strategies of chemotherapy schedules in newly diagnosed participants with metastatic Fusion Positive (alveolar) Rhabdomyosarcoma. The participant and their physician will choose from: Arm A) a first strike therapy, Arm B) a first strike-second strike (maintenance) therapy, Arm C) an adaptively timed therapy, and Arm D) conventional chemotherapy.
Related Latest Advances
Brand Information
- Secondary Malignancy and Leukemia
- Veno-occlusive Disease
- Extravasation
- Myelosuppression
- Immunizations
- Severe Mucocutaneous Reactions
- Renal Toxicity
- Hepatotoxicity
- Potentiation of Radiation Toxicity and Radiation Recall
